DepoMed Inc. (NASDAQ: DEPO) is on The StockGuru Leader Board today.  The stock is up as much as 6.61% on Friday.

Volume traded – so far – as this release was issued intraday:  228,712

Join in on the Discussion about DEPOhttp://members.stockguru.com/stocks/depo/

About the Company:

Depomed, Inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products for neurology, pain, and other central nervous system conditions and diseases. The company offers Gralise tablet, a once-daily formulation of gabapentin for the management of postherpetic neuralgia; and Glumetza metformin hydrochloride extended release tablet that are used as a once-daily treatment for adults with type 2 diabetes. Its product pipeline also comprises Serada, which completed three Phase III clinical trials for the treatment of menopausal hot flashes; and DM-1992 that is in Phase II clinical trials for the treatment of Parkinson’s disease. The company sells its Gralise products to wholesalers and retail pharmacies. It has collaboration or license arrangements with Merck & Co., Inc.; Boehringer Ingelheim International GMBH; Ironwood Pharmaceuticals, Inc.; Janssen Pharmaceutica N.V.; Covidien, Ltd.; Patheon Puerto Rico, Inc.; Valeant Pharmaceuticals International, Inc.; and PharmaNova, Inc. The company was founded in 1995 and is based in Menlo Park, California.

About the StockGuru Leader Board:

We watch for stocks moving up and creating a positive momentum in the market.  We are not compensated for coverage.

Feel free to suggest a stock for coverage if you see it breaking out.  Contact: [email protected].

StockGuru.com 
StockGuruCanada.com 
Shareholdervision.com
BoldStocks.com
IR Affiliates – IRIR.co
StoneBridge Web & SEO – StonebridgeIQ.com

All content on StockGuru.com is original content – with the exception of client news releases. All content is (C) Copyright 2002 to 2012 StockGuru. No content may be used in whole or in part without the express written consent of our Publisher. We encourage web sites interested in our content to offer a reciprocal exchange agreement in exchange for use of some of our content. We do not offer advance approval, but contact our Publisher if you have an interest in repropagating our content. Contact as at: [email protected] or (469) 252-3030. Mailing address: 1601 Berwick Drive; McKinney, Texas 75070